ImmunoPrecise Antibodies Ltd. (IPA)
| Market Cap | 121.31M |
| Revenue (ttm) | 14.75M |
| Net Income (ttm) | -7.89M |
| Shares Out | 19.35M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,283 |
| Open | 6.54 |
| Previous Close | 6.54 |
| Day's Range | 6.22 - 6.64 |
| 52-Week Range | 5.05 - 33.34 |
| Beta | -0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Dec 9, 2021 |
About IPA
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and s...
Financial Performance
In 2021, IPA's revenue was 17.91 million, an increase of 27.41% compared to the previous year's 14.06 million. Losses were -7.34 million, 48.4% more than in 2020.
Financial numbers in millions CADFinancial StatementsNews
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
VICTORIA, British Columbia & CASTRES, France--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmac...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody...
ImmunoPrecise's Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibod...
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibod...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Acc...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody...
ImmunoPrecise SkyRockets On Delta Variant Therapy News: What's Next?
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) skyrocketed 136% on Thursday after the company announced its TATX-03 PolyTope Therapy demonstrated potent pseudovirus neutralizing activity against the COVID-1...
IPA Stock: 7 Things to Know About Covid Vaccine Stock ImmunoPrecise as Shares Rocket 120%
Today's impressive move in ImmunoPrecise's stock price has led investors in IPA stock to consider what is driving these price changes. The post IPA Stock: 7 Things to Know About Covid Vaccine Stock Immu...
Why ImmunoPrecise Antibodies Stock Is Soaring Today
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is surging higher Thursday after the company highlighted the ability of its antibody cocktail to potentially neutralize COVID-19 variants. ImmunoPrecise Antibo...
Immunoprecise Stock Soars As COVID-19 Antibody Cocktail Shows Neutralizing Activity Against Delta Variant In Animal S...
Immunoprecise Antibodies Ltd (NASDAQ: IPA) has announced new results from its TATX-03 PolyTope Therapy, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) va...
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudov...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyT...
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA) (TSX VENTURE:IPA) a leader in full-service, therapeutic antibody disco...
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
VICTORIA, British Columbia--(BUSINESS WIRE)---- $ERF.PA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic di...
Histopathology Preclinical Data from ImmunoPrecise's Polytope™ Program Confirms Lung Inflammation Reduction
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced additional results from its in vivo...
Preclinical Data from ImmunoPrecise's Drug Pipeline to be Presented During the BIO International Partnering Event
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro character...
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program's Path Toward IND Filing
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX venture: IPA) announces the completion of an efficacy-driven, pr...
ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
ImmunoPrecise Launches TATX-112 Antibody Program For Cancer, Alzheimer's Disease
ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary Talem Therapeutics LLC has advanced developing a candidate referred to as TATX-112, against an undisclosed target, into formal lead candidate char...
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...
ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Ac...
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody dis...